shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels
文献类型：期刊论文
| 作者 | Yan Pangke1; Zhang Lina1; Feng Ying1; Qu Hui1; Qin Li1; Zhang Lianshan2; Leng Ying1
|
| 刊名 | actapharmacologicasinica
 |
| 出版日期 | 2014 |
| 卷号 | 35期号:5页码:613 |
| 关键词 | BETA-CELL DIFFERENTIATION IMPROVES GLYCEMIC CONTROL TYPE-2 DIABETES-MELLITUS CHRONIC HYPERGLYCEMIA INSULIN-SECRETION SGLT-2 INHIBITOR SKELETAL-MUSCLE RATS DAPAGLIFLOZIN EMPAGLIFLOZIN sodium glucose cotransporter 2 (SGLT2) SHR3824 dapagliflozin type 2 diabetes mellitus blood glucose insulin sensitivity beta-cell function |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/aps.2013.196 |
| 英文摘要 | Aim: The sodium glucose cotransporter 2 (SGLT2) plays an important role in renal glucose reabsorption, thus serves as a new target for the treatment of diabetes. The purpose of this study was to evaluate SHR3824 as a novel selective SGLT2 inhibitor and to characterize its in vivo effects on glucose homeostasis. The effects of chronic administration of SHR3824 on peripheral insulin sensitivity and pancreatic beta-cell function were also investigated. |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/283697]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 1.中国科学院上海药物研究所 2.Shanghai Hengrui Pharmaceuticals Co, Ltd |
| 推荐引用方式 GB/T 7714 | Yan Pangke,Zhang Lina,Feng Ying,et al. shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels[J]. actapharmacologicasinica,2014,35(5):613. |
| APA | Yan Pangke.,Zhang Lina.,Feng Ying.,Qu Hui.,Qin Li.,...&Leng Ying.(2014).shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels.actapharmacologicasinica,35(5),613. |
| MLA | Yan Pangke,et al."shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels".actapharmacologicasinica 35.5(2014):613. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。